155 related articles for article (PubMed ID: 8479083)
1. [Clinical significance of micromegakaryocytes in de novo AML].
Kobayashi S; Seki K; Katayama N; Akiba C; Yamamoto T; Sakai K; Yamaguchi M; Maruta A; Noguchi T; Ogawa K
Rinsho Ketsueki; 1993 Mar; 34(3):313-20. PubMed ID: 8479083
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis and treatment strategy for de novo AML with trilineage myelodysplasia].
Kuriyama K
Rinsho Ketsueki; 1994 Mar; 35(3):267-71. PubMed ID: 8158847
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and poor outcomes in patients with de novo AML with trilineage myelodysplasia].
Arimura K; Kuriyama K; Miyazaki Y; Nagai K; Fukushima T; Yoshida S; Moriuchi Y; Momita S; Tomonaga M
Rinsho Ketsueki; 1995 Feb; 36(2):98-105. PubMed ID: 7715091
[TBL] [Abstract][Full Text] [Related]
4. The significance of trilineage myelodysplasia in de novo acute myeloblastic leukemia: clinical and laboratory features.
Lima CS; Vassalo J; Lorand-Metze I; Bechelli AP; Souza CA
Haematologia (Budap); 1997; 28(2):85-95. PubMed ID: 9283908
[TBL] [Abstract][Full Text] [Related]
5. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
6. Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
Lemez P; Gáliková J; Haas T
Neoplasma; 2000; 47(1):41-7. PubMed ID: 10870686
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
8. [Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].
Lemez P; Gáliková J; Michalová K; Dvoráková D; MacWhannell A; Zemanová Z; Stejskal J
Vnitr Lek; 2010 Jan; 56(1):37-43. PubMed ID: 20184110
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia.
Nagura E; Minami S; Nagata K; Morishita Y; Takeyama H; Sao H; Suzuki H; Naoe T; Yokomaku S; Mizuno H; Murase T; Hirabayashi N; Takeo T; Tanimoto M; Kawashima K; Saito H
Nagoya J Med Sci; 1999 Nov; 62(3-4):135-44. PubMed ID: 10689875
[TBL] [Abstract][Full Text] [Related]
11. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
12. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
13. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
Castagnola C; Nozza A; Corso A; Bernasconi C
Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
[TBL] [Abstract][Full Text] [Related]
14. Reasons for treating secondary AML as de novo AML.
Ostgård LS; Kjeldsen E; Holm MS; Brown Pde N; Pedersen BB; Bendix K; Johansen P; Kristensen JS; Nørgaard JM
Eur J Haematol; 2010 Sep; 85(3):217-26. PubMed ID: 20456491
[TBL] [Abstract][Full Text] [Related]
15. [Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
Lemez P; Gáliková J; Haas T
Vnitr Lek; 1999 Jun; 45(6):342-6. PubMed ID: 11045169
[TBL] [Abstract][Full Text] [Related]
16. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG;
Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
[TBL] [Abstract][Full Text] [Related]
17. [Proliferation of micromegakaryocytes in acute myelocytic leukemia associated with 5 q- as the sole karyotypic abnormality].
Miura I; Hamanaka SC; Hashimoto K; Nishinari T; Nimura T; Mamiya S; Miura AB
Rinsho Ketsueki; 1993 Apr; 34(4):478-83. PubMed ID: 8510336
[TBL] [Abstract][Full Text] [Related]
18. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features.
Testoni N; Borsaru G; Martinelli G; Carboni C; Ruggeri D; Ottaviani E; Pelliconi S; Ricci P; Pastano R; Visani G; Zaccaria A; Tura S
Haematologica; 1999 Aug; 84(8):690-4. PubMed ID: 10457403
[TBL] [Abstract][Full Text] [Related]
19. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance of CD7 expression in adult acute myeloid leukemia].
Saito T; Usui N; Dobashi N; Maki N; Asai O; Yano S; Kato A; Watanabe H; Katori M; Nagamine M; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Kuraishi Y
Rinsho Ketsueki; 1998 Jul; 39(7):481-6. PubMed ID: 9750454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
